Home › Alcohol Use Disorder (AUD) › NCT07525258

Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

Feasibility and Acceptability of a Novel Implementation Intervention to Promote Alcohol Use Disorder Treatment in Hepatology Clinics

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.

Exclusion Criteria:

* Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.

About the study

The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.

What is being tested

• Implementation Intervention (behavioral)

Sponsor: Yale University · Participants: 30 · Started: Apr 5, 2026

Contact the study team

• Lamia Haque, MD MPH · Phone: (203) 777-0304

Official record on ClinicalTrials.gov — NCT07525258

Locations in the U.S.

Conditions

• Alcohol Use Disorder (AUD)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.